CATB $1.97 ~> News Tomorrow Read ~> (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET.